Celcuity Q3 loss widens on REVTORPYK commercialization costs

Overview

• US biotechnology firm's Q3 saw no product revenue as REVTORPYK shipments began at quarter-end

• Adjusted net loss and adjusted loss per share for Q3 both beat analyst expectations

• Operating expenses rose sharply, driven by commercialization costs for REVTORPYK

Outlook

• Celcuity expects current cash and investments will finance operations through 2029

• Company plans to submit VIKTORIA-1 Phase 3 data to global regulators late 2026 or early 2027

• Randomized Phase 2 prostate cancer study expected to begin in first half of 2027

Result Drivers

• COMMERCIALIZATION COSTS - Co said higher selling, general and administrative expenses were mainly due to hiring and spending to support REVTORPYK launch

• R&D SPENDING - Co said research and development expenses rose mainly due to higher employee-related and manufacturing costs

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Celcuity Inc. is $150.50, about 117.4% above its November 4 closing price of $69.24

Reuters Recommended Reads

• Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall

• Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall

• Nov 5 - Dyne Therapeutics Q3 net loss widens on higher trial costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)